AB Science announces that results from AB8939 preclinical program in acute myeloid leukemia will be presented at the European Hematology Association 2020 Annual Congress
June 10, 2020 15:23 ET | AB Science
Paris, 10 June 2020, 9pm Results from AB8939 preclinical program in acute myeloid leukemia presented at the European Hematology Association (EHA) 2020 Annual Congress AB Science SA (Euronext...
jpg.jpg
Incysus Therapeutics Treats First Patient in Phase 1 Study of Gamma Delta (γδ) T Cell Immunotherapy in Leukemia and Lymphoma Patients Undergoing Allogeneic Stem Cell Transplantation
May 12, 2020 07:00 ET | Incysus Therapeutics, Inc.
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Aptose Biosciences Inc. logo
Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020
April 27, 2020 09:00 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
jpg.jpg
INCYSUS THERAPEUTICS TO PRESENT AT THE 2020 SOLEBURY TROUT VIRTUAL INVESTOR CONFERENCE
April 06, 2020 07:00 ET | Incysus Therapeutics, Inc.
NEW YORK, April 06, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
provectus_logo.jpg
PV-10® Abstract Previously Accepted for Presentation at Terminated American Association for Cancer Research (AACR) Annual Meeting 2020
March 17, 2020 08:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 17, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today said that data from ongoing research into investigational lysosomal-targeting cancer immunotherapy PV-10 (rose bengal...
jpg.jpg
Incysus Therapeutics Announces Issuance of Foundational U.S. Patent Covering Use of Drug Resistant Immunotherapy (DRI) Technology for the Treatment of Cancer
January 29, 2020 07:00 ET | Incysus Therapeutics, Inc.
NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood
December 09, 2019 02:19 ET | AB Science
Paris, 09 December, 2019, 8.30am AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood AB Science SA (NYSE Euronext - FR0010557264 -...
AB Science annonce la publication de trois résumés d’étude de la molécule AB8939 dans l’édition spéciale de la revue Blood consacré au congrès annuel de 'ASH
December 09, 2019 02:19 ET | AB Science
Paris, 9 décembre 2019, 8h30 AB Science annonce la publication de trois résumés d’étudede la molécule AB8939 dans l’édition spéciale de la revue Blood consacréau congrès annuel de...
jpg.jpg
Incysus Therapeutics to Present at the New York Oncology Investor Conference
November 07, 2019 07:00 ET | Incysus Therapeutics, Inc.
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
AB Science announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
November 07, 2019 02:26 ET | AB Science
Paris, November 7, 2019, 8.30am AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA AB Science SA (NYSE Euronext - FR0010557264 - AB) announces today that the U.S. Food and...